Literature DB >> 23933814

TNFR1 determines progression of chronic liver injury in the IKKγ/Nemo genetic model.

F J Cubero1, A Singh, E Borkham-Kamphorst, Y A Nevzorova, M Al Masaoudi, U Haas, M V Boekschoten, N Gassler, R Weiskirchen, M Muller, C Liedtke, C Trautwein.   

Abstract

Death receptor-mediated hepatocyte apoptosis is implicated in a wide range of liver diseases including viral and alcoholic hepatitis, ischemia/reperfusion injury, fulminant hepatic failure, cholestatic liver injury, as well as cancer. Deletion of NF-κB essential modulator in hepatocytes (IKKγ/Nemo) causes spontaneous progression of TNF-mediated chronic hepatitis to hepatocellular carcinoma (HCC). Thus, we analyzed the role of death receptors including TNFR1 and TRAIL in the regulation of cell death and the progression of liver injury in IKKγ/Nemo-deleted livers. We crossed hepatocyte-specific IKKγ/Nemo knockout mice (Nemo(Δhepa)) with constitutive TNFR1(-/-) and TRAIL(-/-) mice. Deletion of TNFR1, but not TRAIL, decreased apoptotic cell death, compensatory proliferation, liver fibrogenesis, infiltration of immune cells as well as pro-inflammatory cytokines, and indicators of tumor growth during the progression of chronic liver injury. These events were associated with diminished JNK activation. In contrast, deletion of TNFR1 in bone-marrow-derived cells promoted chronic liver injury. Our data demonstrate that TNF- and not TRAIL signaling determines the progression of IKKγ/Nemo-dependent chronic hepatitis. Additionally, we show that TNFR1 in hepatocytes and immune cells have different roles in chronic liver injury-a finding that has direct implications for treating chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23933814      PMCID: PMC3792433          DOI: 10.1038/cdd.2013.112

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  46 in total

1.  Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages.

Authors:  Ingo Klein; Judith C Cornejo; Noelle K Polakos; Beena John; Sherry A Wuensch; David J Topham; Robert H Pierce; Ian Nicholas Crispe
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

2.  Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor.

Authors:  Y Yamada; I Kirillova; J J Peschon; N Fausto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.

Authors:  Q Li; D Van Antwerp; F Mercurio; K F Lee; I M Verma
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

Review 4.  Cytokines, STATs and liver disease.

Authors:  Bin Gao
Journal:  Cell Mol Immunol       Date:  2005-04       Impact factor: 11.530

5.  Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis.

Authors:  Núria Tarrats; Anna Moles; Albert Morales; Carmen García-Ruiz; José C Fernández-Checa; Montserrat Marí
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

6.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

7.  Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies.

Authors:  Alexandre Sherlley Casimiro Onofre; Natalia Pomjanski; Birgit Buckstegge; Alfred Böcking
Journal:  Cancer       Date:  2007-08-25       Impact factor: 6.860

Review 8.  Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways.

Authors:  Salvatore Papa; Concetta Bubici; Francesca Zazzeroni; Guido Franzoso
Journal:  Biol Chem       Date:  2009-10       Impact factor: 3.915

9.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

10.  Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor.

Authors:  Y Yamada; E M Webber; I Kirillova; J J Peschon; N Fausto
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

View more
  14 in total

1.  TNFα in liver fibrosis.

Authors:  Yoon Mee Yang; Ekihiro Seki
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

2.  Protein Kinase-Mediated Decision Between the Life and Death.

Authors:  Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout.

Authors:  H Ehlken; S Krishna-Subramanian; L Ochoa-Callejero; V Kondylis; N E Nadi; B K Straub; P Schirmacher; H Walczak; G Kollias; M Pasparakis
Journal:  Cell Death Differ       Date:  2014-06-27       Impact factor: 15.828

4.  Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury.

Authors:  Chongyang Ma; Mengpei Zhao; Yuqiong Du; Shuang Jin; Xiaoyi Wu; Haiyan Zou; Qiuyun Zhang; Lianyin Gao
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-03       Impact factor: 2.629

5.  Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model.

Authors:  M Hatting; M Spannbauer; J Peng; M Al Masaoudi; G Sellge; Y A Nevzorova; N Gassler; C Liedtke; F J Cubero; C Trautwein
Journal:  Cell Death Dis       Date:  2015-03-05       Impact factor: 8.469

6.  Disruption of the FasL/Fas axis protects against inflammation-derived tumorigenesis in chronic liver disease.

Authors:  Francisco Javier Cubero; Marius Maximilian Woitok; Miguel E Zoubek; Alain de Bruin; Maximilian Hatting; Christian Trautwein
Journal:  Cell Death Dis       Date:  2019-02-08       Impact factor: 8.469

7.  Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis.

Authors:  Michele Vacca; Jack Leslie; Samuel Virtue; Brian Y H Lam; Olivier Govaere; Dina Tiniakos; Sophie Snow; Susan Davies; Kasparas Petkevicius; Zhen Tong; Vivian Peirce; Mette Juul Nielsen; Zsuzsanna Ament; Wei Li; Tomasz Kostrzewski; Diana Julie Leeming; Vlad Ratziu; Michael E D Allison; Quentin M Anstee; Julian L Griffin; Fiona Oakley; Antonio Vidal-Puig
Journal:  Nat Metab       Date:  2020-06-08

Review 8.  Balance of inflammatory pathways and interplay of immune cells in the liver during homeostasis and injury.

Authors:  Christer Baeck; Frank Tacke
Journal:  EXCLI J       Date:  2014-02-07       Impact factor: 4.068

9.  Hepatic tissue environment in NEMO-deficient mice critically regulates positive selection of donor cells after hepatocyte transplantation.

Authors:  Michaela Kaldenbach; Francisco Javier Cubero; Stephanie Erschfeld; Christian Liedtke; Christian Trautwein; Konrad Streetz
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

10.  NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.

Authors:  Vangelis Kondylis; Apostolos Polykratis; Hanno Ehlken; Laura Ochoa-Callejero; Beate Katharina Straub; Santosh Krishna-Subramanian; Trieu-My Van; Harald-Morten Curth; Nicole Heise; Falk Weih; Ulf Klein; Peter Schirmacher; Michelle Kelliher; Manolis Pasparakis
Journal:  Cancer Cell       Date:  2015-11-09       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.